178
Participants
Start Date
April 8, 2024
Primary Completion Date
March 1, 2026
Study Completion Date
December 31, 2026
IBI363
IBI363 will be administered as an intravenous (IV) infusion every 2 weeks or every 3 weeks. Subjects will receive study medication until disease progression, toxicity intolerance, withdrawal of consent, the duration of treatment reaches 24 months, or any other reason that requires discontinuation of the study treatment, whichever occurs first.
RECRUITING
BRCR Medical Center, Plantation
RECRUITING
Ocala Oncology Center, Ocala
RECRUITING
Michigan Hematology & Oncology Consultants - MedOnc Troy, Troy
RECRUITING
Michigan Hematology & Oncology Consultants - MedOnc Dearborn, Dearborn
RECRUITING
University of Kansas Medical Center (KUMC), Fairway
RECRUITING
MD Anderson Cancer Center-University of Texas, Houston
RECRUITING
Oncology Consultants P.A., Houston
RECRUITING
University of California, San Francisco (UCSF), San Francisco
RECRUITING
Fred Hutchinson Cancer Center, Seattle
Innovent Biologics (Suzhou) Co. Ltd.
INDUSTRY